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Sir,
We would like to thank Dr Alliot for his comments concerning
our study of metastatic colorectal cancer patients treated with
UFT/LVþL-HOP alternated with UFT/LVþCPT-11 (Petrioli et al,
2004).
In relation to the baseline characteristics of the enrolled
patients, it was pointed out in the Discussion that ‘the performance
status and the percentage of chemonaive patients suggested a
better than average group with regard to efficacy and toxicity’.
As far as metastatic sites are concerned, a selection bias is common
to small phase II studies. It is also worth pointing out that most
of the metastatic colorectal cancer patients enrolled in clinical
trials have p2 metastatic sites (as in our study population).
Furthermore, patients undergoing surgery for colorectal cancer are
unlikely to have metastatic sites other than the liver, lung and
peritoneum, and those having three or more metastatic sites are
unlikely to have a performance status that would allow their
enrolment in a chemotherapeutic protocol. Finally, phase II studies
do not usually report baseline CEA, albumin and LDH levels
because these have little prognostic value in the case of patients
with advanced disease (Douillard et al, 2000; Saltz et al, 2000;
Souglakos et al, 2002; Zeuli et al, 2003).
In relation to the low level of toxicity, it should be remembered
that this was also due to the advantage of oral chemotherapy: that
is, unlike boluses and continuous infusions, the treatment can be
discontinued when toxicity arises and before it worsens (Twelves
and Cassidy, 2002).
About 20% of our patients underwent postchemotherapy
surgery for residual metastases, thus confirming the efficacy of
the proposed chemotherapy protocol. However, postchemotherapy
surgery led to a major advantage in terms of global survival in very
few cases (9%).
The fact that 85% of our patients underwent primary tumour
surgery is said to be a major recruitment bias, but we would like to
point out that this percentage is the same or lower than that
reported in the majority of studies of metastatic colorectal cancer
(Van Cutsem et al, 2001; Twelves et al, 2001; Schilsky et al, 2002;
Falcone et al, 2002).
As mentioned in the Discussion, low dose intensities of L-HOP
and CPT-11 can be expected when using an alternating
chemotherapy regimen. Nevertheless, the results of the study are
supported by other studies of alternating chemotherapy in patients
with metastatic colorectal cancer, suggesting that prolonged
tumour exposure to a fluoropyrimidine plus full doses of L-HOP Published online 6 July 2004
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tolerated (Van Cutsem et al, 1998; Reina et al, 2003; Aparicio et al,
2003). Furthermore, it needs to be remembered that an aggressive
chemotherapeutic approach can lead to numerous dose adjust-
ments and delays, which inevitably lower the planned dose
intensities, and it is difficult to continue the treatment over time
(Falcone et al, 2002; Souglakos et al, 2002; Ychou et al, 2003).
Concerning the possibility of using higher doses of UFT, we
would like to point out that we chose a fixed dose of
250mgm
 2day
 1 for 28 days on the basis of the activity and
tolerability of UFT/LVþL-HOP or UFT/LVþCPT-11 demon-
strated by previous phase I/II studies (Price and Hill, 2000;
Vanhoefer and Wilke, 2001). The risk of overlapping diarrhoea is
certainly greater with the combination of UFT/LV and CPT-11, and
so higher UFT doses could perhaps be used in combination with L-
HOP. However, other studies are difficult to interpret in this sense
because they used shorter UFT administration schedules (21 days),
which reduce the risk of diarrhoea (Kim et al, 2002; MacKay et al,
2003).
We believe that the hypothesis that more patients might have
benefited from heavier regimens is difficult to support. Although
54% of the patients were candidates for a second surgical
intervention, the albeit low 7.3% rate of complete remission (CR),
which is considered the main indicator of treatment efficacy, was
s i m i l a rt ot h a to b s e r v e dw i t hm u c hm o r ea g g r e s s i v ec h e m o t h e r a p y
regimens in patients with similar characteristics to those of our
study population (Buyse et al, 2000; Saltz et al, 2000; Falcone et al,
2002; Souglakos et al, 2002). This suggests that the CR rate is more
related to the biological characteristics of the tumour than the
chemotherapy dose. We have obtained similar CR rates in previous
clinical trials using the simple schedule of folinic acid and 5-
fluorouracil (Francini et al, 1988; Petrioli et al,1 9 9 5 ) .
In relation to the possible selection of resistant clones,
the rationale of an alternating schedule is to ensure that full
doses of all active agents can be administered by avoiding the
potential incidence of overlapping side effects that may occur
with concomitant drug administration. Our results suggest
that a treatment based on low dose intensities of the more active
drugs can be administered for a long time with a high level of
tolerability, and similar response, time to progression and survival
rates to those observed using more aggressive chemotherapy
regimens (Douillard et al, 2000; Saltz et al, 2000; Souglakos et al,
2002).
Dr Alliot also raises the question of second-line chemotherapy,
but this is a known problem when more active drugs are used.
Furthermore, the results of second-line chemotherapies are
generally unsatisfactory, whereas the simultaneous use of all of
the drugs active in first-line treatment is an attempt to improve
prognosis and many studies are investigating this approach
(Falcone et al, 2002; Ychou et al, 2003).
Finally, we agree that, in a subgroup of patients with initially
unresectable metastatic colorectal cancer, active first-line che-
motherapy may permit secondary radical surgery of metastases,
and this was also possible in our study population (Bismuth et al,
1996). Furthermore, neoadjuvant treatments play an important
role in all types of neoplasms. However, the aim of our study was
not to develop a neoadjuvant treatment but a new chemotherapy
regimen that could improve patient compliance and reduce side
effects. In the absence of phase I data concerning the recom-
mended dose of a three-drug combination, we chose to alternate
the previously explored combinations of UFT/LVþCPT-11 and
UFT/LVþL-HOP and, albeit with all of the limitations of a small
phase II study, the results seemed to be interesting because of the
association of efficacy and little toxicity.
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